Weiyuan Bio
微远生物
elsewhere's corpus does not cover Weiyuan Bio as a subject in its own right. The entity card lists the name but provides no facts, and none of the retrieved chunks describe the company directly. The name appears only in passing within a 道彤投资 (Dalton Investment) portfolio update about other firms [^C1–C3], with no information about what Weiyuan Bio does, when it was founded, or who runs it.
AI-generated — may contain errors, please verify.
Weiyuan BioCompany
微远生物
No graph yet
Mentioned in 3 articles
Coverage
A Decade of Dalton, Igniting a New Chapter of Intelligence | Dalton Venture's 2025 Annual Partners Meeting and 10th Anniversary Forum Concludes Successfully
Together, Toward the Brilliance and Distant Horizons of the Next Decade
Vol. 2 The "Efficiency Code" of Bio-Manufacturing: AI Gives Enzymes a 7-Day Iteration Engine | Column · The New Era's Unicorns
The bio-manufacturing industry will undergo structural transformation around 2030.
